Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
May 21, 2024 09:35 ET
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
Multiomics Market Size, Share & Trends Analysis Report 2024-2030: Decreasing Costs of Omics Technologies, Public Players are Expected to Drive Expansion
May 21, 2024 09:30 ET
|
Research and Markets
Dublin, May 21, 2024 (GLOBE NEWSWIRE) -- The "Multiomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables), By Type (Single-cell, Bulk), By...
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
May 21, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
May 20, 2024 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new...
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
May 20, 2024 07:03 ET
|
Wugen
Wugen Announces RMAT and PRIME Designations for WU-CART-007 and Plans to Present Positive Phase 2 Study Findings at EHA 2024
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
May 17, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in...
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 16, 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis...
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
May 16, 2024 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
May 15, 2024 16:05 ET
|
Athira Pharma, Inc.
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Global Flow Cytometry Market Report 2024-2029, Featuring Agilent Technologies, BD, Bio-Rad Laboratories, Cytek Biosciences, Danaher, Miltenyi Biotec, Sony Biotechnology and Standard Biotools
May 15, 2024 09:48 ET
|
Research and Markets
Dublin, May 15, 2024 (GLOBE NEWSWIRE) -- The "Flow Cytometry: Products, Technologies and Global Markets 2024-2029" report has been added to ResearchAndMarkets.com's offering. The global market...